Skip to main content
Larimar Therapeutics, Inc. logo

Larimar Therapeutics, Inc. — Investor Relations & Filings

Ticker · LRMR ISIN · US98885E1038 LEI · 529900NCBZHTTJV6HX73 US Professional, scientific and technical activities
Open in API
Filings indexed 666 across all filing types
Latest filing 2019-01-24 Director's Dealing
Country US United States of America
Listing US LRMR

About Larimar Therapeutics, Inc.

https://larimartx.com/

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company utilizes a proprietary intracellular delivery platform to design fusion proteins that deliver therapeutic molecules to targets within cells. Its lead product candidate, nomlabofusp (formerly CTI-1601), is a recombinant fusion protein being evaluated in a Phase 2 clinical program for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics plans to leverage its platform to develop additional therapies for other rare diseases characterized by deficiencies in intracellular proteins.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2019-01-24 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it is a press release about new data from a Phase 2 Clinical Trial, furnished as an exhibit. The document explicitly states that the information is "furnished" and not "filed," and it is a short document (3283 characters) primarily announcing the press release. There are no financial statements or detailed financial data included. This fits the profile of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into other specific categories like Earnings Release or Annual Report. Therefore, the correct classification is Regulatory Filings (RNS).
2019-01-17 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is used for current reports to announce major events that shareholders should know about. The content describes a press release about the FDA placing a clinical hold on a clinical trial application. There is no financial data, no detailed report, no earnings information, or management discussion. The document is short (2826 characters) and primarily serves as a regulatory announcement of an event. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-11-26 English
Regulatory Filings 2018
Regulatory Filings
2018-11-21 English
Regulatory Filings 2018
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-3. It references Rule 461 under the Securities Act of 1933 and discusses procedural matters related to the registration statement's effectiveness. There is no financial data, report content, or detailed disclosures typical of financial reports. The document is a regulatory communication related to a filing process rather than a report itself. The document length is short (2669 characters) and it is clearly an announcement/request related to a regulatory filing. Therefore, it fits best under Regulatory Filings (RNS) as a procedural correspondence with the SEC.
2018-11-16 English
Regulatory Filings 2018
Regulatory Filings
2018-11-15 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.